Search

EPC2407

It is intended for the treatment of advanced cancer patients with solid tumors that are well vascularized. … EPC2407 is a novel small molecule vascular disruption agent and apoptosis inducer for the treatment of patients with advanced solid tumors and lymphomas.

Erythroxylum catuaba bark

[A215262] The infusion is thought to carry stimulant and aphrodisiac effects,[A215262] and catuaba made specifically with _Trichilia catigua_ has been investigated for use in depression.[A215267] … "Catuaba" is a general term for a medicinal infusion created by the bark of plants belonging to the _Erythroxylum_ genus, though this name is also applied to infusions of plants belonging to other genera

CD68-ET3-LV

CD68-ET3-LV is an autologous gene therapy consisting of CD34+ hematopoietic stem and progenitor cells transduced ex-vivo with the CD68-ET3-LV lentiviral vector.

Octamoxin

This drug was used in the past as an antidepressant agent in the 1960s, however, has since been discontinued. … Octamoxin, also known as _2-octylhydrazine_, is both an irreversible and nonselective monoamine oxidase enzyme inhibitor (MAOI) of the _hydrazine_ chemical class.

Cenplacel-L

Cenplacel-L is under investigation in clinical trial (Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Ischemic Stroke) for the treatment of patients

D2C7 immunotoxin

D2C7-IT is under investigation in clinical trial NCT04160494 (D2C7-IT With Atezolizumab for Recurrent Gliomas). … D2C7 immunotoxin (D2C7-IT) is an investigational dual-specific monoclonal antibody targeting EGFRwt and EGFRvIII with a genetically engineered form of the _Pseudomonas exotoxin_, PE38-KDEL.

DLO6002

DLO6002 is developed by Summit Corporation and is in phase I of clinical trials for the treatment of Parkinson's disease.

PB127

Zenarestat

V24343

The anti-obesity drug, V24343, acts by targeting the CB1 receptor in the brain and suppressing a person's appetite.